Bayer AG (FRA:BAYN) Receives €80.63 Average Price Target from Brokerages

Share on StockTwits

Bayer AG (FRA:BAYN) has been given an average recommendation of “Hold” by the twenty-four ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is €80.67 ($93.81).

A number of equities research analysts have recently issued reports on BAYN shares. Credit Suisse Group set a $43.00 target price on SEA and gave the company a “buy” rating in a research note on Thursday, July 4th. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the company a “buy” rating in a research note on Thursday, June 27th. Barclays increased their target price on Intuit from $225.00 to $237.00 and gave the company an “equal weight” rating in a research note on Friday, May 24th. Independent Research set a €290.00 ($337.21) target price on adidas and gave the company a “neutral” rating in a research note on Friday, June 28th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $70.00 target price on shares of Total in a research note on Monday, July 15th.

Shares of BAYN stock traded up €0.79 ($0.92) during trading hours on Friday, reaching €59.55 ($69.24). The company had a trading volume of 3,075,454 shares. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98). The company’s fifty day simple moving average is €56.65.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: What is a capital gains distribution?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine
Unum Therapeutics  Price Target Lowered to $13.00 at Wedbush
Unum Therapeutics Price Target Lowered to $13.00 at Wedbush
Zendesk  Research Coverage Started at Compass Point
Zendesk Research Coverage Started at Compass Point
Afya  Coverage Initiated at Bank of America
Afya Coverage Initiated at Bank of America
Telefonica  Downgraded to “Neutral” at Bank of America
Telefonica Downgraded to “Neutral” at Bank of America


 
© 2006-2019 Zolmax.